Drug Profile
SB 267268
Alternative Names: 267268; SB-267268Latest Information Update: 03 Mar 2008
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Aminopyridines; Eye disorder therapies; Osteoporosis therapies; Small molecules
- Mechanism of Action Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Age-related macular degeneration; Postmenopausal osteoporosis
Most Recent Events
- 27 Feb 2006 Phase-I clinical trials in Age-related macular degeneration (unspecified route)
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 18 Apr 2000 Preclinical development for Postmenopausal osteoporosis in USA (Unknown route)